Datopotamab deruxtecan

Datopotamab deruxtecan

Oncology

Indication extension

Breast cancer

Datopotamab deruxtecan as monotherapy is indicated for the treatment of adult patients with locally recurrent inoperable or metastatic Triple-Negative Breast Cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy.

Daiichi Sankyo

Daiichi Sankyo

Antibody-drug conjugate

Intravenous

Injection / infusion solution

Intermural (MSZ)

Centralised (EMA)

Normal trajectory

New therapeutical formulation

No

2024

2025

No

Clinical trials

Single-agent chemotherapy (eribulin, capecitabine, carboplatin, paclitaxel, Nab-paclitaxel)

No estimate possible yet

Er zijn nog geen resultaten bekend uit deTROPION-Breast02 studie.

1 times every 3 weeks

6,0 mg/kg

TROPION-Breast02 (NCT05374512)

Pakketadvies sluisgeneesmiddel sacituzumab govitecan (Trodelvy®) voor de behandeling van inoperabele of uitgezaaide borstkanker, ZIN 2022

In het pakketadvies wordt een patiëntvolume van 277 ingeschat.

Not yet known

Not yet known

There is currently nothing known about off label use.

Yes

Treatment of adult patients with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations (NCT04656652). Treatment of adult patients with inoperable or metastatic HR-Positive, HER2-negative Breast Cancer who have been treated with one or two prior lines of systemic chemotherapy (NCT05104866). Treatment of adult patients with advanced or metastatic NSCLC without actionable genomic alterations whose tumor has high programmed death-ligand 1 (PD-L1) expression and who have not previously received systemic therapy for advanced or metastatic NSCLC (NCT05215340).

Manufacturer

There is currently no further information available.